Literature DB >> 30861207

c-Abl kinase regulates neutrophil extracellular trap formation, inflammation, and tissue damage in severe acute pancreatitis.

Raed Madhi1, Milladur Rahman1, Matthias Mörgelin2, Henrik Thorlacius1.   

Abstract

Neutrophil extracellular traps (NETs) are involved in acute pancreatitis (AP) but mechanisms controlling NET expulsion in AP are incompletely understood. Herein, we examined the role of c-Abelson (c-Abl) kinase in NET formation and tissue damage in severe AP. AP was induced by taurocholate infusion into pancreatic duct or intraperitoneal administration of l-arginine in mice. Pancreatic, lung, and blood samples were collected and levels of phosphorylated c-Abl kinase, citrullinated histone 3, DNA-histone complexes, myeloperoxidase, amylase, cytokines, and CXC chemokines were quantified. Citrullinated histone 3, reactive oxygen species (ROS), and NET formation were determined in bone marrow neutrophils. Taurocholate challenge increased phosphorylation of c-Abl kinase and levels of citrullinated histone 3 in the pancreas as well as DNA-histone complexes in the plasma. Administration of the c-Abl kinase inhibitor GZD824 not only abolished activation of c-Abl kinase but also decreased levels of citrullinated histone 3 in the pancreas and DNA-histone complexes in the plasma of animals with AP. Moreover, GZD824 decreased plasma levels of amylase, IL-6, and MMP-9 as well as edema, acinar cell necrosis, hemorrhage, CXC chemokine formation, and neutrophil infiltration in the inflamed pancreas. A beneficial effect of c-Abl kinase inhibition was confirmed in l-arginine-induced pancreatitis. In vitro, inhibition of c-Abl kinase reduced TNF-α-induced formation of ROS, histone 3 citrullination, and NETs in isolated bone marrow neutrophils. Our findings demonstrate that c-Abl kinase regulates NET formation in the inflamed pancreas. In addition, inhibition of c-Abl kinase reduced pancreatic tissue inflammation, and damage in AP. Thus, targeting c-Abl kinase might be a useful way to protect the pancreas in severe AP. ©2019 Society for Leukocyte Biology.

Entities:  

Keywords:  adhesion; chemokines; histones; leukocyte; pancreas

Mesh:

Substances:

Year:  2019        PMID: 30861207     DOI: 10.1002/JLB.3A0618-222RR

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  6 in total

Review 1.  Targeting neutrophil extracellular traps in severe acute pancreatitis treatment.

Authors:  Jing Hu; Hongxin Kang; Huan Chen; Jiaqi Yao; Xiaolin Yi; Wenfu Tang; Meihua Wan
Journal:  Therap Adv Gastroenterol       Date:  2020-11-24       Impact factor: 4.409

2.  Pancreatic ductal deletion of S100A9 alleviates acute pancreatitis by targeting VNN1-mediated ROS release to inhibit NLRP3 activation.

Authors:  Hong Xiang; Fangyue Guo; Xufeng Tao; Qi Zhou; Shilin Xia; Dawei Deng; Lunxu Li; Dong Shang
Journal:  Theranostics       Date:  2021-03-04       Impact factor: 11.556

Review 3.  Damage associated molecular patterns and neutrophil extracellular traps in acute pancreatitis.

Authors:  Xiaoying Zhou; Shengchun Jin; Jingyi Pan; Qingyi Lin; Shaopeng Yang; Peter C Ambe; Zarrin Basharat; Vincent Zimmer; Wei Wang; Wandong Hong
Journal:  Front Cell Infect Microbiol       Date:  2022-08-12       Impact factor: 6.073

Review 4.  Roles, detection, and visualization of neutrophil extracellular traps in acute pancreatitis.

Authors:  Hongxuan Li; Lingyu Zhao; Yueying Wang; Meng-Chun Zhang; Cong Qiao
Journal:  Front Immunol       Date:  2022-08-05       Impact factor: 8.786

5.  Dasatinib regulates LPS-induced microglial and astrocytic neuroinflammatory responses by inhibiting AKT/STAT3 signaling.

Authors:  Ka-Young Ryu; Hyun-Ju Lee; Hanwoong Woo; Ri-Jin Kang; Kyung-Min Han; HyunHee Park; Sang Min Lee; Ju-Young Lee; Yoo Joo Jeong; Hyun-Wook Nam; Youngpyo Nam; Hyang-Sook Hoe
Journal:  J Neuroinflammation       Date:  2019-10-26       Impact factor: 8.322

6.  Drug discovery and formulation development for acute pancreatitis.

Authors:  Xue Jiang; Ya-Wen Zheng; Shihui Bao; Hailin Zhang; Ruijie Chen; Qing Yao; Longfa Kou
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.